FdaApplication
NDA 208051
Identifiers
- fda_app_no: NDA208051
Properties
| Property | Value |
|---|---|
| applicant_name | PUMA BIOTECHNOLOGY INC |
| application_type | NDA |
| approval_date | 2017-07-17 |
Revenue by product
NERLYNX
| Period | Revenue |
|---|---|
| Q2 2026 | $53.6M |
| Q1 2026 | $42.0M |
| Q3 2025 | $51.9M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NERLYNX | NERATINIB MALEATE | EQ 40MG BASE | TABLET;ORAL |
1 product